Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia

Frontiers in Genetics

Volumn 3, Issue JAN, 2013, Pages

  Stocco, Gabriele ^a,b   Franca, Raffaella ^c   Verzegnassi, Federico ^c   Londero, Margherita ^b,d   Rabusin, Marco ^c   Decorti, Giuliana ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^d Ospedale di San Daniele del Friuli   (Italy)

Author keywords

Acute lymphoblastic leukemia; ITPA; Mercaptopurine; Multilocus genotypes; PACSIN2; Pharmacogenetics; TPMT

Indexed keywords

EID: 84876184498     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00309     Document Type: Review

References (56)

1. Adam de Beaumais, T., Dervieux, T., Fakhoury, M., Medard, Y., Azougagh, S., Zhang, D., et al. (2010). The impact of high-dose methotrexate on intracellular 6- mercaptopurine disposition dur- ing interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 66, 653-658.
2. Advani, S., Pai, S., Venzon, D., Adde, M., Kurkure, P. K., Nair, C. N., et al. (1999). Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann. Oncol. 10, 167-176.
3. Cheok, M. H., and Evans, W. E. (2006). Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6, 117-129.
4. Consortium, C. P. I. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) Gene-drug pairs [Online]. Available at: http://www.pharmgkb.org/page/ cpicGeneDrugPairs [accessed Oct 22, 2012].
5. Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., PanzerGrumayer, R., Moricke, A., et al. (2010). Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 115, 3206-3214.
6. D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Baietto, L., Simiele, M., et al. (2012). Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirinassociate anemia in patients receiving standard anti-HCV treatment. Ther. Drug. Monit. 34, 165-170.
7. Dervieux, T., Wessels, J. A., Kremer, J. M., Padyukov, L., Seddighzadeh, M., Saevarsdottir, S., et al. (2012). Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet. Genomics 22, 1-9.
8. Dorababu, P., Nagesh, N., Linga, V. G., Gundeti, S., Kutala, V. K., Reddanna, P., et al. (2012a). Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6- mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68, 379-387.
9. Dorababu, P., Naushad, S. M., Linga, V. G., Gundeti, S., Nagesh, N., Kutala, V. K., et al. (2012b). Genetic variants of thiopurine and folate metabolic pathways determine 6-MPmediated hematological toxicity in childhood ALL. Pharmacogenomics 13, 1001-1008.
10. Fellay, J., Thompson, A. J., Ge, D., Gumbs, C. E., Urban, T. J., Shianna, K. V., et al. (2010). ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405-408.
11. Gilbert-Diamond, D., and Moore, J. H. (2011). Analysis of gene-gene interactions. Curr. Protoc. Hum. Genet. Chap. 1, Unit1 14.
12. Hahn, L. W., Ritchie, M. D., and Moore, J. H. (2003). Multifactor dimensionality reduction software for detecting gene-gene and geneenvironment interactions. Bioinfor- matics 19, 376-382.
13. Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., et al. (2011). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629.
14. Kawedia, J. D., Kaste, S. C., Pei, D., Panetta,J. C.,Cai,X.,Cheng,C.,et al. (2011). Pharmacokinetic, pharma- codynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117, 2340-2347, quiz 2556.
15. Kim, H., Kang, H. J., Kim, H. J., Jang, M. K., Kim, N. H., Oh, Y., et al. (2012). Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE 7:e45558. doi:10.1371/journal.pone.0045558.
16. Krishnamurthy, P., Schwab, M., Take- naka, K., Nachagari, D., Morgan, J., Leslie, M., et al. (2008). Transportermediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 68, 4983-4989.
17. Lennard, L., and Lilleyman, J. S. (1989). Variable mercaptopurine metabo- lism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 7, 1816-1823.
18. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. (2008). SLCO1B1 variants and statin-induced myopathy - a genome wide study. N. Engl. J. Med. 359, 789-799.
19. Lopez-Lopez, E., Martin-Guerrero, I., Ballesteros, J., Pinan, M. A., GarciaMiguel, P., Navajas, A., et al. (2011). Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 57, 612-619.
20. Marino, S., Verzegnassi, F., Tamaro, P., Stocco, G., Bartoli, F., Decorti, G., et al. (2009). Response to gluco- corticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr. Blood Cancer 53, 984-991.
21. Marsh, S., and Van Booven, D. J. (2009). The increasing complexity of mercaptopurine pharmacoge- nomics. Clin. Pharmacol. Ther. 85, 139-141.
22. McDonagh, E. M., Whirl-Carrillo, M., Garten, Y., Altman, R. B., and Klein, T. E. (2011). From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5, 795-806.
23. Menezes, M. R., Waisertreiger, I. S., Lopez-Bertoni, H., Luo, X., and Pavlov, Y. I. (2012). Pivotal role of inosine triphosphate pyrophosphatase in maintaining genome stability and the prevention of apoptosis in human cells. PLoS ONE 7:e32313. doi:10.1371/journal.pone.0032313.
24. Moore,J. H.,andWilliams,S. M. (2009). Epistasis and its implications for personal genetics. Am. J. Hum. Genet. 85, 309-320.
25. Ochi, H., Maekawa, T., Abe, H., Hayashida, Y., Nakano, R., Kubo, M., et al. (2010). ITPA polymor- phism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 139, 1190-1197.
26. Okada, Y., Nakamura, K., Hiromura, K., Nojima, Y., Horiuchi, R., and Yamamoto, K. (2009). Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin. Pharmacol. Ther. 85, 527-530.
27. Paugh,S.W.,Stocco,G.,and Evans,W. E. (2010). Pharmacogenomics in pediatric leukemia. Curr. Opin. Pediatr. 22, 703-710.
28. Paugh, S. W., Stocco, G., McCorkle, J. R., Diouf, B., Crews, K. R., and Evans, W. E. (2011). Cancer pharmacogenomics. Clin. Pharmacol. Ther. 90, 461-466.
29. Pinto, N., Cohn, S. L., and Dolan, M. E. (2012). Using germline genomics to individualize pediatric cancer treatments. Clin. Cancer Res. 18, 2791-2800.
30. Pottier, N., Cheok, M. H., Yang, W., Assem, M., Tracey, L., Obenauer, J. C., et al. (2007). Expression of SMARCB1 modulates steroid sensitivity inhumanlymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum. Mol. Genet. 16, 2261-2271.
31. Pottier,N.,Yang,W.,Assem,M.,Panetta, J. C., Pei, D., Paugh, S. W., et al. (2008). The SWI/SNF chromatinremodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J. Natl. Cancer Inst. 100, 1792-1803.
32. Pui, C. H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., et al. (2009). Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741.
33. Pui, C. H., and Evans, W. E. (2006). Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178.
34. Pui, C. H., Mullighan, C. G., Evans, W. E., and Relling, M. V. (2012). Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120, 1165-1174.
35. Ramsey, L. B., Bruun, G. H., Yang, W., Trevino, L. R., Vattathil, S., Scheet, P., et al. (2012). Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrex- ate disposition. Genome Res. 22, 1-8.
36. Relling, M. V., Altman, R. B., Goetz, M. P., and Evans, W. E. (2010). Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507-509.
37. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., et al. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391.
38. Relling, M. V., and Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467.
39. Relling, M. V., Pui, C. H., Cheng, C., and Evans, W. E. (2006). Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843-844.
40. Schrappe, M., Valsecchi, M. G., Bartram, C. R., Schrauder, A., PanzerGrumayer, R., Moricke, A., et al. (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118, 2077-2084.
41. Schwab, M., and Brauch, H. (2012). Fighting Drug Fail- ure [Online]. Available at: http://www.fightingdrugfailure.net/ [accessed Oct 22, 2012].
42. Stocco, G., Cheok, M. H., Crews, K. R., Dervieux, T., French, D., Pei, D., et al. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172.
43. Stocco, G., Crews, K. R., and Evans, W. E. (2010). Genetic polymorphism of inosine- triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin. Drug. Saf. 9, 23-37.
44. Stocco, G.,Yang,W., Crews, K. R., Thierfelder, W. E., Decorti, G., Londero, M., et al. (2012). PACSIN2 poly- morphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum. Mol. Genet. 21, 4793-4804.
45. Swen, J. J., Nijenhuis, M., De Boer, A., Grandia, L., Maitland-Van Der Zee, A. H., Mulder, H., et al. (2011). Pharmacogenetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673.
46. Swen, J. J., Wilting, I., De Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., et al. (2008). Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787.
47. Tanaka, Y., Manabe, A., Nakadate, H., Kondoh, K., Nakamura, K., Koh, K., et al. (2012). The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk. Res. 36, 560-564.
48. Thompson,A. J., Fellay, J., Patel, K., Tillmann, H. L., Naggie, S., Ge, D., et al. (2010). Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139, 1181-1189.
49. Trevino, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., et al. (2009). Germline genetic vari- ation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972-5978.
50. von Ahsen, N., Oellerich, M., and Armstrong,V. W. (2008). Character- ization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther. Drug. Monit. 30, 16-22.
51. Wheeler, H. E., and Dolan, M. E. (2012). Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 13, 55-70.
52. Yamamoto, K., Okada, Y., Nakamura, K., Hiromura, K., Nojima, Y., and Nakamura, T. (2010). Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin. Drug. Saf. 9, 447-457.
53. Yang, J. J., Cheng, C., Devidas, M., Cao, X., Campana, D., Yang, W., et al. (2012). Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120, 4197-4204.
54. Yang, J. J., Cheng, C., Devidas, M., Cao, X., Fan, Y., Campana, D., et al. (2011). Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237-241.
55. Yang, J. J., Cheng, C., Yang, W., Pei, D., Cao, X., Fan, Y., et al. (2009). Genome-wide interroga- tion of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393-403.
56. Zaza, G., Cheok, M., Krynetskaia, N., Thorn, C., Stocco, G., Hebert, J. M., et al. (2010). Thiopurine pathway. Pharmacogenet. Genomics 20, 573-574.